[{"data":1,"prerenderedAt":135},["ShallowReactive",2],{"naujienos/eu-investment-incentive-to-boost-ai-medical-innovation/en":3},{"status":4,"data":5},true,{"image":6,"id":14,"seo":15,"title":12,"date":90,"url":86,"fullUrl":26,"text":91,"excerpt":25,"more":92,"tags":133,"temos":134},{"src":7,"is_svg":8,"ratio":9,"width":10,"height":11,"alt":12,"caption":13},"https://web-prod.inovacijuagentura.lt/wp-content/uploads/2022/12/gedeminas-2-3840x2560.jpg",false,0.6666666666666666,3840,2560,"EU Investment Incentive to Boost AI Medical Innovation","",7035,{"title":16,"robots":17,"og_locale":23,"og_type":24,"og_title":16,"og_description":25,"og_url":26,"og_site_name":27,"article_publisher":28,"og_image":29,"twitter_card":34,"schema":35,"breadcrumbs":78,"description":13,"language":87},"EU Investment Incentive to Boost AI Medical Innovation - Inovacijų agentūra",{"index":18,"follow":19,"max-snippet":20,"max-image-preview":21,"max-video-preview":22},"index","follow","max-snippet:-1","max-image-preview:large","max-video-preview:-1","en_US","article","EU investment has helped technology company Oxipit develop its ChestLink artificial intelligence (AI) solution for radiology. ChestLink automatically recognises X-ray images of healthy patients and produces their final descriptions. It is the world’s first AI-based radiology solution capable of diagnosing a patient without any intervention by a physician.","https://www.inovacijuagentura.lt/en/naujiena/eu-investment-incentive-to-boost-ai-medical-innovation/","Inovacijų agentūra","https://www.facebook.com/inovacijuagentura",[30],{"width":31,"height":32,"url":7,"type":33},"4337","2891","image/jpeg","summary_large_image",{"@context":36,"@graph":37},"https://schema.org",[38,53,55,65,69],{"@type":39,"@id":26,"url":26,"name":16,"isPartOf":40,"primaryImageOfPage":42,"image":44,"thumbnailUrl":7,"datePublished":45,"breadcrumb":46,"inLanguage":48,"potentialAction":49},"WebPage",{"@id":41},"https://www.inovacijuagentura.lt/en/#website",{"@id":43},"https://www.inovacijuagentura.lt/en/naujiena/eu-investment-incentive-to-boost-ai-medical-innovation/#primaryimage",{"@id":43},"2022-12-21T22:00:00+00:00",{"@id":47},"https://www.inovacijuagentura.lt/en/naujiena/eu-investment-incentive-to-boost-ai-medical-innovation/#breadcrumb","en-US",[50],{"@type":51,"target":52},"ReadAction",[26],{"@type":54,"inLanguage":48,"@id":43,"url":7,"contentUrl":7,"width":31,"height":32,"caption":12},"ImageObject",{"@type":56,"@id":47,"itemListElement":57},"BreadcrumbList",[58,63],{"@type":59,"position":60,"name":61,"item":62},"ListItem","1","Home","https://www.inovacijuagentura.lt/en/",{"@type":59,"position":64,"name":12},"2",{"@type":66,"@id":41,"url":62,"name":27,"description":13,"publisher":67,"inLanguage":48},"WebSite",{"@id":68},"https://www.inovacijuagentura.lt/en/#organization",{"@type":70,"@id":68,"name":27,"url":62,"logo":71,"image":76,"sameAs":77},"Organization",{"@type":54,"inLanguage":48,"@id":72,"url":73,"contentUrl":73,"width":74,"height":75,"caption":27},"https://www.inovacijuagentura.lt/en/#/schema/logo/image/","https://web-prod.inovacijuagentura.lt/wp-content/uploads/2026/05/ia-logo-main.svg","1886","786",{"@id":72},[28],[79,82,85],{"url":80,"text":61,"id":81},"/en/",7576,{"url":83,"text":84},"/en/news/","News",{"url":86,"text":12,"id":14},"/en/naujiena/eu-investment-incentive-to-boost-ai-medical-innovation/",[88],{"url":26,"code":89,"locale":89,"default":8},"en","2022-12-22","\u003Cp style=\"text-align:justify\">The ChestLink solution is designed to facilitate the work of radiologists in primary care centres. In clinics where various preventive tests and examinations are carried out or where patients come for minor medical conditions, more than 50% of chest radiographs show no abnormalities. Nevertheless, doctors still have to review and describe these images. To save doctors’ time, the ChestLink AI system can do this job for them.\u003C/p>\n\u003Cp style=\"text-align:justify\">“There is a worldwide shortage of radiologists. Patients have to wait for weeks to get an X-ray description. The shortage of doctors has a direct impact on the quality of patient treatment. ChestLink is able to automate up to 40% of the workload of a primary care centre's radiology department, allowing doctors to focus on pathologies where abnormalities are detected,” said Gediminas Pekšys, CEO of Oxipit.\u003C/p>\n\u003Cp style=\"text-align:justify\">The ChestLink solution has been positively evaluated and successfully used by medical institutions in Lithuania and other European countries.\u003C/p>\n\u003Cp style=\"text-align:justify\">The AI solution developed by Oxipit is based on high-performance data science models which can identify that a patient is healthy with 99.8% accuracy. The EU investment has covered much of the technical work for this product, such as data labelling and model development.  \u003C/p>\n\u003Cp style=\"text-align:justify\">After developing the technical components of the product, Oxipit took care of the certification and market introduction of the product. In April 2022, ChestLink was awarded CE certification, allowing the solution to be used in healthcare facilities in 32 European countries.\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cstrong>\u003Cspan style=\"color:black\">Two projects – Two Successes \u003C/span>\u003C/strong>\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cspan style=\"color:black\">Implementation of ChestLink is linked to the EU’s investment call \u003Cem>Eksperimentas\u003C/em>, which has helped companies develop innovations that bring real benefits to society. The final phase of the project required an investment of almost \u003C/span>\u003Cspan style=\"color:black\">€\u003C/span>\u003Cspan style=\"color:black\">600,000. Of them, \u003C/span>\u003Cspan style=\"color:black\">€\u003C/span>\u003Cspan style=\"color:black\">400,000 were allocated from EU funds, while the remaining costs were covered by the company's own resources. \u003C/span>\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cspan style=\"color:black\">“Medical innovations often take decades to develop. Scientists have long proclaimed that in the future, AI in radiology will be able to diagnose patients autonomously – but no one expected it to happen as early as 2022. The incentive from EU funds was significant to develop this solution sooner,” said Mr Pekšys.  \u003C/span>\u003C/p>\n\u003Cp style=\"text-align:justify\">The whole process of developing ChestLink took about four years. The present AI product was developed as a follow-up to the previous EU investment call \u003Cem>Intelektas\u003C/em>. This included the development of models for the detection of lung cancer, tuberculosis and other pathologies.\u003C/p>\n\u003Cp style=\"text-align:justify\">“To be able to recognise that a patient is healthy, the AI must first be able to recognise even the smallest lung pathologies,” noted Mr Pekšys.\u003C/p>\n\u003Cp style=\"text-align:justify\">Models for identifying cancerous lesions in the lungs are also used in another Oxipit product, Oxipit Quality. This product acts as a virtual assistant to the doctor, reviewing each X-ray image and the doctor's existing description of it in real time. If the AI solution detects abnormalities in the radiograph which have been overlooked by the doctor, a message is sent to the radiologist to review the test again.\u003C/p>\n\u003Cp style=\"text-align:justify\">“Focal cancerous lesions are extremely small and difficult to see with the naked eye. They account for over 80% of all undetected pathologies. The earlier the lesion is detected, the more successful the subsequent cancer treatment and the better the patient’s prognosis. According to a study carried out at Kaunas City Outpatient Clinic and Šeškinė Outpatient Clinic, Oxipit Quality is able to detect 20% more focal lesions and to start the treatment of patients earlier,’ said Mr Pekšys.\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cstrong>\u003Cspan style=\"color:black\">Consistent Investment in Innovation \u003C/span>\u003C/strong>\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cspan style=\"color:black\">Over \u003C/span>\u003Cspan style=\"color:black\">€\u003C/span>\u003Cspan style=\"color:black\">310 million have already been invested in business research and experimental development in the 2014-2020 funding period, with 251 projects completed and 236 ongoing. \u003C/span>\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cspan style=\"color:black\">The programme will result in a total of 864 innovative product prototypes. Some companies develop several prototypes in a single project. The calls were distributed consistently throughout the period to ensure that research and experimental development (R&D) activities in the companies could continue uninterrupted, as was the case for Oxipit.\u003C/span>\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cspan style=\"background-color:white\">\u003Cspan style=\"color:#282338\">“\u003C/span>\u003C/span>\u003Cspan style=\"color:#282338\">To further stimulate the supply of innovation, we plan to launch the \u003Cem>InoStartas \u003C/em>call later this year. Its main activities will enable researchers to participate in R&D projects in companies, pilot production and market readiness of newly developed products. We are also planning to launch two more calls early next year: \u003Cem>InoPažanga\u003C/em> and \u003Cem>InoBranda\u003C/em> for the deployment of R&D innovations,” said Agnė Vaitkūnienė, Director of the Investment Management Department of the Innovation Agency.\u003C/span>\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cem>\u003Cspan style=\"color:black\">InoStart\u003C/span>\u003C/em>\u003Cspan style=\"color:black\">as, \u003Cem>InoPažanga\u003C/em> and \u003Cem>InoBranda\u003C/em> are part of the 2022-2030 Economic Transformation and Competitiveness Development Programme managed by the Ministry of the Economy and Innovation of the Republic of Lithuania. The project activities are financed by the EU investment funds.\u003C/span>\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cspan style=\"color:black\">All calls are published on the \u003C/span>\u003Ca href=\"https://kc.inovacijuagentura.lt/kcis/finansines-priemones/finansavimo-priemones?lang=lt\">\u003Cspan style=\"color:#0563c1\">website\u003C/span>\u003C/a>\u003Cu> \u003C/u>\u003Cspan style=\"color:black\">of Innovation Agency's funding instruments. \u003C/span>\u003C/p>\n",[93,102,111,125],{"image":94,"title":97,"url":98,"id":99,"text":100,"temos":101},{"src":95,"is_svg":8,"ratio":96,"alt":97,"caption":13},"https://web-prod.inovacijuagentura.lt/wp-content/uploads/2026/05/kosmoso-memorandumas-su-polsa.jpg",0.6669921875,"Lithuania Strengthens Cooperation with Poland and the United States in the Space Sector: Important Memorandums Signed","/en/naujiena/lithuania-strengthens-cooperation-with-poland-and-the-united-states-in-the-space-sector-important-memorandums-signed/",6748,"Lithuania’s space sector continues to strengthen international partnerships and expand cooperation with key players in the global space industry. Innovation Agency Lithuania has recently signed two significant memorandums of understanding – with the Polish Space Agency (POLSA) and the U.S. space infrastructure company Vast. These agreements open new opportunities for Lithuanian businesses, research institutions, and international projects.",[],{"image":103,"title":106,"url":107,"id":108,"text":109,"temos":110},{"src":104,"is_svg":8,"ratio":105,"alt":106,"caption":13},"https://web-prod.inovacijuagentura.lt/wp-content/uploads/2026/03/shutterstock-2539768243-1.jpg",0.7490234375,"Lithuania Ranks First in Europe in the Global Entrepreneurship Index","/en/naujiena/lithuania-ranks-first-in-europe-in-the-global-entrepreneurship-index/",6892,"The latest Global Entrepreneurship Monitor (GEM) 2025/2026 global report shows that Lithuania is the leading country in Europe in terms of the quality of its entrepreneurial environment and ranks among the world’s strongest economies in this field.",[],{"image":112,"title":114,"url":115,"id":116,"text":117,"temos":118},{"src":113,"is_svg":8,"ratio":96,"alt":114,"caption":13},"https://web-prod.inovacijuagentura.lt/wp-content/uploads/2026/01/karolina-urbonaite.jpg","Lithuania’s Startup Ecosystem Surpasses €16.4 Billion in Value: Investments Jump 1.7x in 2025","/en/naujiena/lithuanias-startup-ecosystem-surpasses-e16-4-billion-in-value-investments-jump-1-7x-in-2025/",6999,"The total value of Lithuania’s startup ecosystem reached €16.4 billion in 2025, according to the latest Dealroom report initiated by Startup Lithuania, a division of the Innovation Agency. In just one year, Lithuanian startups attracted €220 million in venture capital investments from 77 unique investors. The ecosystem’s growing maturity was further confirmed earlier this year with the addition of a new unicorn to Lithuania’s startup map — Cast AI.",[119,122],{"id":120,"name":121},577,"Growth",{"id":123,"name":124},579,"Innovation",{"image":126,"title":128,"url":129,"id":130,"text":131,"temos":132},{"src":127,"is_svg":8,"ratio":96,"alt":128,"caption":13},"https://web-prod.inovacijuagentura.lt/wp-content/uploads/2025/12/modix-fgf-3d-spausdintuvas-2.jpg","Mission-Driven Innovations: Science and Business Shaping Lithuania’s Future","/en/naujiena/mission-driven-innovations-science-and-business-shaping-lithuanias-future/",6904,"Some important scientific research activities and innovative business-developed products may sound complex – unsurprisingly, as they are developed by people who dedicate their entire lives to these fields. Yet behind these sophisticated terms lie concrete solutions that will eventually make each of our daily lives easier. Where science and business join forces, more accurate disease diagnostics for the health of us and our loved ones are developed, cybersecurity tools are created to protect the country, and climate-neutral production technologies and materials emerge to help preserve our nature and resources.",[],[],[],1780325204744]